Clinical trial · Interventional
Prostate Cancer Antigen 3 (PCA-3) Gene Project
PCA-3 Gene Project
NCT01177436CI-TRIAL-00015506completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nowadays, prostate cancer screening is largely widespread although it is not recommended yet. This screening includes primarily digital rectal examination and PSA. Recently, a new specific genetic marker of prostate cancer has been discovered. It is PCA-3 gene. The main objective is to evaluate prospectively this new marker in patients treated for prostatic pathology (benign or malign) in the department.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Prostatic Hypertrophy | Benign Prostatic Hyperplasia | ALIAS | 0.90 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Taking of urines | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients treated for prostatic pathology
- description
- Patients treated for prostatic pathology (benign or malign)in the hospital department.
- interventionNames
- Biological: Taking of urines
Primary outcomes (1)
- measure
- To evaluate the specificity and the sensibility of PCA-3 marker in patients treated for prostatic pathology (benign or malign).
- timeFrame
- 18 months
Secondary outcomes (1)
- measure
- To analyse expression of several other prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2)in the aim to improve the prostate cancer diagnosis specificity.
- timeFrame
- 18 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients operated for a prostate cancer or a benign prostatic hypertrophy * Patients not in state of emergency Exclusion Criteria: * Patients with an urinary infection proved bacteriologically * Patients with a vesical malign disease * Patients in state of emergency
References
Publications (0)
Data not yet available
No reference posted for this study.